Locoregional Therapies in the Treatment of 3- to 5-cm Hepatocellular Carcinoma: Critical Review of the Literature
Shamar Young, Jafar Golzarian
Abstract
Combination therapy with transarterial chemoembolization (TACE) and ablation has the most robust and highest level of evidence to support its efficacy and therefore should be considered first-line therapy for nonresectable HCCs that measure 3-5 cm. The studies support that TACE followed by ablation is superior to either TACE alone or ablation alone. Data for transarterial radioembolization (TARE) to treat HCCs in this specific size range are very limited. Additional data are needed about the comparative effectiveness of TACE-ablation combination and TARE and how the TACE-ablation combination compares with surgical resection.
Topics & Concepts
MedicineHepatocellular carcinomaCarcinomaOncologyInternal medicineGeneral surgeryHepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentHepatitis B Virus Studies